Citigroup writes for Edwards Lifescinces EW that the "PARTNER Cohort B trial data forms the basis for the
company's PMA filing and we believe SAPIEN will be approved by the FDA in 2H11. Now that the primary endpoint hurdles have been met, we believe the investment debate will shift to market adoption with a focus on support, training
and delivery. In addition, we believe new embolic protection devices will also receive attention in order to address vascular and stroke-related complications."
Citigroup maintains its Buy rating and $60 price target.
Edward Lifesciences closed yesterday at $59.70.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorNewsOfferingsAnalyst RatingsCitigroupEdwards LifesciencesHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in